Few pantry staples carry as much health baggage as cinnamon. For two decades it has been pitched as a natural blood-sugar fix — a claim that traces back to a single 2003 study of 60 people in Pakistan that reported dramatic drops in glucose and cholesterol. That study turned cinnamon into a supplement-aisle superstar, but in 2025 its own journal flagged it with an “expression of concern,” and the meta-analyses that followed tell a messier story: cinnamon does lower fasting blood sugar, but the effect is modest, the trials disagree with each other wildly, and the effect on long-term blood-sugar control (HbA1c) may not be there at all. Then there is the part almost nobody mentions — the “cinnamon” in your spice rack is usually cassia, a cousin species that contains coumarin, a compound that can damage your liver. Here is what the evidence actually says, the parts that hold up and the parts that don’t.
📋 Simple Summary
Cinnamon is a spice that has a real but modest effect on blood sugar. Across three big meta-analyses of randomized trials, taking cinnamon lowered fasting blood sugar by roughly 10 to 25 mg/dL — enough to matter on a lab report, but not enough to replace medication. The catch is that the trials are all over the place (scientists call this “high heterogeneity”), and cinnamon does not reliably lower HbA1c, which is the 3-month average of blood sugar and the number doctors actually care about most. On top of that, the original 2003 study that started the whole craze was flagged in 2025 with an “expression of concern” by its own journal. And there is a safety catch most people miss: the common “cassia” cinnamon sold in supermarkets contains coumarin, a compound that can harm the liver in daily high doses — so if you take it every day, you should use Ceylon (“true”) cinnamon instead. Bottom line: cinnamon is a Silver-tier compound — a cheap, easy, mostly-safe way to nudge blood sugar in the right direction, but it is a small lever, not a longevity breakthrough.
The detailed breakdown continues below for those who want the full science.
Published: August 16, 2026
Evidence Tier: 🥈 Silver — consistent but modest fasting-glucose benefit across multiple meta-analyses; high trial heterogeneity, no reliable HbA1c effect, and a flagged foundational study
Category: Supplements & Compounds
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Talk to your doctor before taking any supplement — especially if you have liver disease, take blood-sugar-lowering or blood-thinning medication, or are pregnant. The information below is for education only.
✅ Pros (What the Evidence Supports)
- Consistently lowers fasting blood sugar: Three meta-analyses of randomized trials (10, 16, and 18 studies) all found cinnamon reduced fasting glucose, by roughly 10–25 mg/dL (PMID 24019277, 31425768, 30935562).
- Improves insulin resistance: A 2019 meta-analysis of 16 trials found cinnamon lowered HOMA-IR, a measure of insulin resistance, by a significant margin (PMID 31425768).
- Also improves blood lipids: A 2013 meta-analysis found cinnamon lowered total cholesterol, LDL, and triglycerides while raising HDL (PMID 24019277).
- Cheap, widely available, and safe at normal food amounts: Cinnamon is inexpensive and has a long history of safe culinary use; side effects are mild at reasonable doses.
❌ Cons (What the Evidence Doesn’t Support or Warns About)
- No reliable HbA1c benefit: The effect on long-term blood-sugar control (HbA1c) is inconsistent — one meta-analysis found no effect, another only a borderline 0.24% drop (PMID 24019277, 30935562).
- Extreme trial disagreement: Statistical heterogeneity is very high (up to I² = 96.5%), meaning individual trials contradict each other, which weakens confidence in any single number (PMID 30935562).
- Foundational study flagged: The landmark 2003 study that launched the cinnamon craze received an “expression of concern” from Diabetes Care in 2025 (PMID 14633804, 40834253).
- Coumarin liver risk in cassia cinnamon: The common cassia variety contains coumarin, which can damage the liver at daily high doses — enough that a single teaspoon can exceed the safe limit (PMID 20024932, 19680836).
What Is Cinnamon?
Cinnamon is a spice made from the dried inner bark of trees in the Cinnamomum genus. It has been used as food and medicine for thousands of years, but modern health claims rest on two groups of compounds: cinnamaldehyde, the aromatic oil that gives cinnamon its smell (55–85% of the bark’s essential oil) and drives much of its anti-inflammatory and antimicrobial activity, and type-A procyanidins, a family of polyphenols that appear to improve how cells respond to insulin (PMID 42169286).
Here is the part that matters most for anyone buying it: there is more than one kind of “cinnamon,” and they are not equal. The spice sold as plain “cinnamon” in most supermarkets is cassia cinnamon (Cinnamomum cassia, sometimes labeled Chinese cinnamon or Korintje/Indonesian C. burmannii). It is cheap and strong-flavored, and it is also relatively high in coumarin, a naturally occurring compound that can be toxic to the liver (PMID 20024932). The other main type is Ceylon cinnamon (Cinnamomum verum, also called “true cinnamon”), which is milder and sweeter and contains only trace amounts of coumarin (PMID 19680836). Ceylon costs more, which is why most commercial cinnamon is cassia — and why studies explicitly warn that Ceylon is frequently adulterated with cheaper, higher-coumarin species (PMID 37599847, 38266436).
Cinnamon is not an “anti-aging” molecule in the way rapamycin or NMN are. Its longevity relevance is indirect: it helps with blood-sugar control and insulin sensitivity, and chronically high blood sugar is one of the most reliable accelerators of aging through a process called glycation — the same process behind the advanced glycation end products (AGEs) that stiffen tissues and drive age-related disease.
How It Works
Cinnamon is unusually promiscuous — it hits several targets at once, which is part of why it is interesting and part of why the trials are so noisy (PMID 42169286):
- It slows starch digestion. Cinnamon inhibits the enzymes alpha-amylase and alpha-glucosidase, which break down carbohydrates in the gut. Slowing that breakdown blunts the spike in blood sugar after a meal — the same mechanism as the prescription drug acarbose (PMID 42169286).
- It helps insulin work better. The type-A procyanidins activate insulin-signaling pathways inside cells — specifically PI3K/Akt and AMPK — which increases the movement of glucose transporters (GLUT4) to the cell surface, pulling sugar out of the blood (PMID 42169286). This is the mechanism most often credited for the glucose-lowering effect.
- It reduces glucose production and inflammation. Cinnamon and cinnamaldehyde suppress glucose output from the liver and dial down inflammatory signaling, including the cGAS-STING pathway implicated in metabolic disease (PMID 42169286, 42178077).
- It blocks glycation. In lab models, cinnamon extracts reduced the formation of advanced glycation end products (AGEs) — the sugar-damaged proteins that accumulate with age and high blood sugar (PMID 42508027). This is the most direct “anti-aging” mechanism on the list, though it is in-vitro evidence, not human proof.
- It talks to your gut bacteria. Cinnamon’s polyphenols and procyanidins need gut microbes to be converted into their active forms, and researchers now think differences in people’s microbiomes may explain a large chunk of why cinnamon trials disagree so much (PMID 42597565). In mice, cinnamon polysaccharides reshaped the gut microbiome, improved mitochondrial function, and delayed age-related tissue degeneration (PMID 42492267) — intriguing, but animal data only.
The Longevity Connection
🍬 Blood sugar and glycation — the main story, but a modest one. This is where cinnamon’s evidence actually lives. The cleanest result comes from a 2013 meta-analysis by Allen and colleagues in Annals of Family Medicine, pooling 10 randomized trials (543 people with type 2 diabetes) using 120 mg to 6 g of cinnamon a day for 4 to 18 weeks: fasting glucose dropped by 24.59 mg/dL, total cholesterol by 15.60 mg/dL, LDL by 9.42 mg/dL, and triglycerides by 29.59 mg/dL, while HDL rose by 1.66 mg/dL (PMID 24019277). A 2019 meta-analysis of 16 trials found a smaller but still significant fasting-glucose drop (about 0.55 mmol/L, roughly 10 mg/dL) plus a significant improvement in insulin resistance (PMID 31425768), and an 18-trial meta-analysis the same year found a 19.26 mg/dL drop in fasting glucose (PMID 30935562). Three independent teams, three consistent directions. The honest caveat: the effect on HbA1c — the 3-month average that predicts complications — was not significant in two of those analyses and only borderline (0.24%) in the third (PMID 24019277, 30935562, 31425768). So cinnamon nudges the day-to-day number, but there is no solid proof it meaningfully improves long-term glucose control.
🫀 Cardiometabolic health. The same 2013 meta-analysis found consistent improvements in blood lipids, which is why cinnamon gets marketed for heart health (PMID 24019277). But the effect sizes are small, the heterogeneity is high, and no trial has shown cinnamon reduces actual heart attacks or deaths. Treat this as a mild, supportive benefit, not a cardiovascular intervention.
🦠 The microbiome angle — the most interesting frontier. The newest research points at the gut as the missing piece. A 2026 review argues that a large share of cinnamon’s trial-to-trial inconsistency (the I² > 75% seen in meta-analyses) may come down to whether your gut bacteria can convert cinnamon’s polyphenols and procyanidins into their active metabolites (PMID 42597565). In a 2026 mouse study, cinnamon polysaccharides reshaped the gut microbiota — enriching a bacterium called Alloprevotella rava — which improved choline metabolism and mitochondrial function and delayed aging-related tissue degeneration (PMID 42492267). This is genuinely exciting mechanistic work, but it is preclinical: mice, not people. It is a reason to watch cinnamon research, not a reason to expect an anti-aging effect today.
🧠 Brain — early and unproven. In lab models, cinnamon extracts reduced the clumping of a disease-linked protein (ataxin-3) in a model of a hereditary neurodegenerative disease (PMID 42513188), and a 2026 review summarizes animal evidence that cinnamon may protect the gut and blood-brain barriers in autoimmune disease (PMID 42513192). These are intriguing leads with no human trials behind them.
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| Allen 2013 (PMID 24019277) | Meta-analysis, 10 RCTs, N=543 (type 2 diabetes) | Fasting glucose −24.59 mg/dL; TC/LDL/TG down, HDL up; no significant HbA1c effect; I² 66.5–94.7%. |
| Zare 2019 (PMID 31425768) | Meta-analysis, 16 RCTs (T2DM + pre-diabetes) | Fasting glucose −0.545 mmol/L; HOMA-IR −0.714; no significant HbA1c or lipid change; I² ~84%. |
| Namazi 2019 (PMID 30935562) | Meta-analysis, 18 RCTs (type 2 diabetes) | Fasting glucose −19.26 mg/dL; HbA1c −0.24% (borderline); no weight/BMI effect; I² 96.5%. |
| Khan 2003 (PMID 14633804) | RCT, N=60 (type 2 diabetes), 1–6 g/day, 40 days | Reported large glucose/lipid improvements; received an Expression of Concern in 2025 (PMID 40834253). |
| Abraham 2010 (PMID 20024932) | Toxicology / risk assessment review | Coumarin is hepatotoxic and possibly carcinogenic; tolerable daily intake set at 0.1 mg/kg body weight. |
| Lungarini 2008 (PMID 19680836) | Chemical analysis (cinnamon sold in Italy) | Cassia cinnamon is high in coumarin; Ceylon (“true”) cinnamon has only trace amounts. |
| Species discrimination 2023 (PMID 37599847) | Chemical profiling of 4 Cinnamomum species | Confirms C. verum (Ceylon) is low-coumarin; cassia/burmannii/loureiroi are higher-coumarin and often used to adulterate Ceylon. |
| 2026 mechanisms review (PMID 42169286) | Critical review, >150 studies | Maps cinnamaldehyde + type-A procyanidin mechanisms (enzyme inhibition, insulin signaling, gut microbiota). |
| Microbiome moderator 2026 (PMID 42597565) | Hypothesis / review | Proposes gut-microbe “metabotypes” explain much of cinnamon’s high trial heterogeneity (I² > 75%). |
| Mammary aging 2026 (PMID 42492267) | Preclinical (mouse model) | Cinnamon polysaccharides reshaped gut microbiota and delayed age-related tissue degeneration — animal data only. |
Dosing and Safety
The dosing picture is simple but the safety picture is where most people go wrong:
| Context | Dose Used | Notes |
|---|---|---|
| Blood-sugar support (typical) | 1–2 g/day (≈ half a teaspoon) | A sensible starting point; split with meals to blunt post-meal glucose spikes. |
| Range used in trials | 1–6 g/day (up to ~2 teaspoons) | The 1–6 g range covers almost every clinical trial (PMID 24019277, 31425768). |
| Safety ceiling | Keep coumarin under ~0.1 mg/kg/day | That is ~6 mg coumarin for a 60 kg (132 lb) adult — the tolerable daily intake (PMID 20024932). |
The coumarin problem, in plain numbers. The safe limit for coumarin is about 0.1 mg per kilogram of body weight per day — roughly 6 mg a day for a 60 kg (132 lb) adult (PMID 20024932). Cassia cinnamon is roughly 0.3–0.8% coumarin by weight, so a single level teaspoon (about 2.6 g) can deliver 8–20 mg of coumarin — already over the safe limit. Ceylon cinnamon, by contrast, has only trace amounts, which is why daily high-dose users should specifically choose Ceylon (PMID 19680836, 37599847). The liver damage from coumarin is real — it is the reason European regulators set the limit in the first place — but it builds up over time with chronic daily use, not from the occasional sprinkle in your coffee or oatmeal.
Form selection. The two realistic choices:
- Ceylon cinnamon (“true cinnamon”): low coumarin, sweeter and milder. The right choice if you take cinnamon daily as a supplement or in large amounts.
- Cassia cinnamon (standard supermarket cinnamon): high coumarin, stronger flavor. Fine for ordinary culinary use, but not ideal for daily high-dose supplementation.
Side effects and interactions:
- Liver toxicity (coumarin). The headline risk from long-term, high-dose cassia use. Avoid if you have liver disease, and prefer Ceylon for daily use (PMID 20024932).
- Mouth and skin irritation. Cinnamaldehyde can irritate the mouth and, in some people, trigger allergic contact dermatitis on the skin (PMID 19680836).
- Blood-sugar-lowering medication. Cinnamon can add to the effect of metformin, insulin, or other glucose-lowering drugs, raising the risk of hypoglycemia. Monitor glucose if you combine them.
- Blood thinners (warfarin). Coumarin is chemically related to warfarin (a coumarin derivative). The interaction from dietary coumarin is not the main concern — the liver risk is — but anyone on anticoagulants should check with a doctor.
- Pregnancy. Normal food amounts are fine, but high doses are not well studied — keep to culinary use during pregnancy.
- Dry powder inhalation. Swallowing a spoonful of dry cinnamon powder can irritate the throat and lungs if it is inhaled — the reason for the viral “cinnamon challenge” injuries. Mix it into food or liquid instead.
❓ Common Questions About Cinnamon
What is cinnamon and how does it work?
Cinnamon is a spice made from the dried inner bark of trees in the Cinnamomum family. The compounds that matter most are cinnamaldehyde (which gives it its smell and anti-inflammatory effect) and a group of polyphenols called type-A procyanidins, which appear to make your cells respond better to insulin. Cinnamon also slows the digestion of starch by blocking the enzymes that break it down, which blunts the rise in blood sugar after a meal.
What does the evidence actually show?
The evidence is mixed but leans positive for one thing: fasting blood sugar. Across three meta-analyses of randomized trials, cinnamon lowered fasting glucose by roughly 10 to 25 mg/dL — a real but modest effect. However, the trials disagree with each other a lot (high heterogeneity), and cinnamon does not reliably lower HbA1c, the 3-month average of blood sugar. That is why the overall tier is Silver rather than Gold.
What’s the right dose?
Most trials used 1 to 6 grams a day, which is about half a teaspoon to two teaspoons. A common starting point is 1 to 2 grams (roughly half a teaspoon) daily, usually split with meals. If you take it every day at these higher amounts, choose Ceylon (“true”) cinnamon rather than cassia, because cassia contains coumarin, which can harm the liver.
What are the risks and side effects?
Cinnamon is safe in normal food amounts. The two real concerns are coumarin and irritation. Cassia cinnamon (the common supermarket kind) contains coumarin, which can damage the liver if you take large amounts daily; Ceylon cinnamon has only trace amounts. Cinnamaldehyde can irritate the mouth and cause allergic skin reactions in some people, and large dry spoonfuls of the powder can irritate the throat or lungs if inhaled.
Who should avoid it?
People with liver disease should avoid high-coumarin cassia cinnamon and stick to Ceylon or skip it. Anyone on blood-sugar-lowering medication (like metformin or insulin) should monitor glucose closely, because cinnamon can add to the effect and cause blood sugar to drop too low. Pregnant women should keep to normal food amounts, since high doses are not well studied. If you are on warfarin, check with your doctor, because coumarin compounds can interact with blood clotting.
The Bottom Line
Cinnamon genuinely lowers fasting blood sugar, but the effect is modest and the foundation is shakier than most people realize. Three independent meta-analyses point the same direction — fasting glucose down by roughly 10 to 25 mg/dL — which is a real, reproducible signal (PMID 24019277, 31425768, 30935562). But the same analyses show enormous trial-to-trial disagreement, no reliable HbA1c benefit, and the field’s foundational 2003 study has since been flagged with an expression of concern (PMID 14633804, 40834253). Taken together, cinnamon is a weak-to-moderate tool for day-to-day glucose, not a strong one, and certainly not a replacement for metformin or lifestyle change.
The coumarin issue is the one thing everyone should internalize. If you are going to take cinnamon every day, the specific species matters more than the dose. Standard cassia cinnamon can push you over the coumarin safety limit with a single daily teaspoon, while Ceylon cinnamon is effectively coumarin-free. The people most at risk are exactly the people most likely to self-treat with cinnamon — those with insulin resistance or type 2 diabetes — so the “natural and therefore safe” assumption is the real hazard here.
Our verdict: 🥈 Silver. A cheap, easy, mostly-safe way to nudge blood sugar in the right direction — but a small lever with a flagged foundation and a real species-dependent safety caveat. Who it’s for: people with mildly elevated fasting glucose or insulin resistance who want a low-cost adjunct to diet and exercise (using Ceylon cinnamon, 1–2 g/day with meals). Who it’s not for: anyone expecting a longevity breakthrough, anyone with liver disease, people already on glucose-lowering medication without monitoring, and anyone unwilling to check that their cinnamon is actually Ceylon. The fundamentals — sleep, exercise, and eating fewer refined carbohydrates — will move your blood sugar far more than any amount of cinnamon will.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Cinnamon is a food and is not approved to diagnose, treat, cure, or prevent any disease. Its blood-sugar effects are modest and most trials involved people who already had type 2 diabetes or pre-diabetes, not healthy individuals. Always consult a qualified healthcare provider before starting any supplement, especially if you have liver disease, take blood-sugar-lowering or anticoagulant medication, or are pregnant or breastfeeding. Read our full disclaimer →
Sources
- Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Allen RW, et al. Ann Fam Med. 2013. PMID 24019277
- Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: a meta-analysis and meta-regression. Diabetes Res Clin Pract. 2019. PMID 31425768
- The impact of cinnamon on anthropometric indices and glycemic status in patients with type 2 diabetes: a systematic review and meta-analysis of clinical trials. Namazi N, et al. Complement Ther Med. 2019. PMID 30935562
- Cinnamon improves glucose and lipids of people with type 2 diabetes. Khan A, et al. Diabetes Care. 2003. PMID 14633804
- Expression of Concern: Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2025. PMID 40834253
- Toxicology and risk assessment of coumarin: focus on human data. Abraham K, et al. Mol Nutr Food Res. 2010. PMID 20024932
- Coumarin and cinnamaldehyde in cinnamon marketed in Italy: a natural chemical hazard? Lungarini S, et al. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008. PMID 19680836
- Discrimination of four Cinnamomum species by proximate, antioxidant, and chemical profiling. J Food Sci Technol. 2023. PMID 37599847
- Application of HPLC-UV combined with chemometrics for the detection and quantification of ‘true cinnamon’ adulteration. Talanta. 2024. PMID 38266436
- A critical appraisal of anti-hyperglycemic mechanisms, matrix-dependent bioavailability, and species-stratified safety of Cinnamomum spp. as functional food ingredients. Food Res Int. 2026. PMID 42169286
- Re-evaluation of the anti-glycation activity of herbal extracts using multiple anti-glycation assays. Biosci Biotechnol Biochem. 2026. PMID 42508027
- The gut microbiome as a plausible but unproven moderator of cinnamon trial outcomes in type 2 diabetes. Front Nutr. 2026. PMID 42597565
- Cinnamon polysaccharides reshape gut microbiota and enrich Alloprevotella rava to promote acetate-dependent choline metabolism and delay mammary aging. Phytomedicine. 2026. PMID 42492267
- Hydroxycinnamic acids target COPII cargo sorting machinery to attenuate inflammation via the cGAS-STING axis. J Ethnopharmacol. 2026. PMID 42178077
- Polyphenol-rich cinnamon bud extract affects ataxin-3 aggregation and ameliorates SCA3 phenotypes. Molecules. 2026. PMID 42513188
- Intestinal and blood-brain barrier dysfunction in lupus: emerging mechanisms and modulation by cinnamon. Molecules. 2026. PMID 42513192
- Role of spices in the management of diabetes and gestational diabetes. Rev Med Suisse. 2026. PMID 42210833